Integrity Bio has announced the validation of its second fill/finish manufacturing line. This plant expansion more than doubles the company’s manufacturing capacity to meet growing demand in the field.
Founded in 2003, Integrity Bio has established itself as a provider of Formulation Development, GMP Fill Finish Services, and Innovative Drug Delivery technologies to support biotechnology and pharmaceutical companies large and small who strive to save or improve the quality of human life through innovative medicine.
“Customer demand for our fill/finish services drove us to make the investment in a brand-new manufacturing line,” said Michael Reilly, CEO of Integrity Bio. “The validation timing could not have been better. The new capacity allows us to prioritize COVID-19 projects.”
Geno Worke, senior director of operations added, “We are really excited about this second line. It complements our first line by integrating a number of key new features that customers have asked for, such as a restricted access barrier system (aka RABS), and increased speed with an automatic vial washing and depyrogenation tunnel attached. The new line allows us to fill over 20,000 liquid vials in a single batch which obviously means we can handle bigger projects for our clients.”
